Rheumatology Highlights Report
Do you have 15 minutes? A patient cancelled an
appointment or you finished a meeting early? Give us
15 minutes and we will give you the world of rheumatology.
The Rheumatology Highlights Report is designed for the busy clinician. It is designed to provide highlights from key scientific presentations and/or abstracts presented at international and national rheumatology meetings. Clinical experts attending these meetings have selected the most significant data to report. Each activity includes a 15-minute presentation with supporting materials and commentary on the clinical implications of the data.
Target Audience
Rheumatologists are the primary audience for these activities, as well as other health care professionals managing patients with rheumatic disease, including primary care practitioners, internists, and cardiologists.
Webcast |
||
 |
Miscellaneous Rheumatic Disorders | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
 |
Systemic Lupus Erythematosus: Pathology, Diagnosis, and Treatment | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
 |
Cardiovascular Aspects of Rheumatic Disease | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
 |
Rheumatoid Arthritis: Non-biologics, Including DMARD Therapy – Advances in Efficacy and Safety | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
 |
Metabolic Bone Disease | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
 |
Psoriatic Arthritis | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
|
Rheumatoid Arthritis: Clinical Aspects, Outcomes, and Measures | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
|
Vasculitis: Pathology, Diagnosis, and Treatment | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
|
Ankylosing Spondylitis | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
|
Rheumatoid Arthritis: Biologic DMARD - Safety | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
|
Rheumatoid Arthritis: Biologic DMARD - Efficacy | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
|
Advances in Basic Science | |
Estimated Time: 15 minutes |
Technical Requirements: Windows Media |
|
Series Objectives
- Summarize results from rheumatic disease research studies and clinical trials and assess their clinical practice impact.
- Review presented data on safety and efficacy of biologic use in RA treatment models.
- Describe new data on the pathophysiology of cardiovascular disease in patients with rheumatic disease.
- Evaluate research on advances in biologics including TNF inhibitors, T cell inhibitors, B cell inhibitors, and new biologic therapies.
- Analyze the impact of research on diagnosis and treatment for ankylosing spondylitis, psoriatic arthritis, vasculitis, systemic lupus, and metabolic bone disease.
- Discuss salient advances in basic science, including immunologic-oriented genetics, protease research, and pathogenetic research.
Activity Director
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman, Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
